Hormonal
SGLT2 inhibitors reduce cardiovascular death, heart failure hospitalizations, and kidney disease progression in patients with cardio-renal-metabolic syndrome, regardless of diabetes status.
If you have heart failure, chronic kidney disease, or type 2 diabetes with high cardiovascular risk, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs protect your heart and kidneys, not just your blood sugar, and work even if you don't have diabetes. The benefits are substantial and supported by major clinical trials.
Research has confirmed that their unique beneficial effects extend beyond glycemic control, reducing CV death and hospitalizations in patients with heart failure, and the incidence of kidney failure in dedicated kidney outcome studies—regardless of diabetes status.
Why this rating
The claim is supported by multiple large-scale, landmark randomized controlled trials (DAPA-HF, EMPEROR-Reduced, DAPA-CKD, etc.) with consistent, statistically significant results.
Source
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Konstantinos Grigoriou et al. · Medicina · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →